Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors

Modern Pathology

Volumn 27, Issue 3, 2014, Pages 332-342

  Chan, Aden Ka Yin ^a   Pang, Jesse Chung Sean ^a   Chung, Nellie Yuk Fei ^a   Li, Kay Ka Wai ^a   Poon, Wai Sang ^a   Chan, Danny Tat Ming ^a   Shi, Zhifeng ^b   Chen, Liang ^b   Zhou, Liangfu ^b   Ng, Ho Keung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b FUDAN UNIVERSITY   (China)

Author keywords

CIC; FUBP1; Immunohistochemistry; Mutation; Oligoastrocytoma; Oligodendroglioma

Indexed keywords

BINDING PROTEIN; FAR UPSTREAM ELEMENT BINDING PROTEIN 1; HOMOLOG OF DROSOPHILA CAPICUA PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BRAIN TUMOR; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE INACTIVATION; GENE LOSS; GENE MUTATION; GENE SEQUENCE; GENETIC CORRELATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NULL ALLELE; OLIGODENDROGLIAL TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SOMATIC MUTATION;

ADULT; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DISEASE-FREE SURVIVAL; DNA HELICASES; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; OLIGODENDROGLIOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRESSOR PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896740505     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.165     Document Type: Article

References (33)

1. van den Bent MJ, Reni M, Gatta G, et al. Oligodendroglioma. Crit Rev Oncol Hematol 2008;66: 262-272.
2. Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145: 1175-1190.
3. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90: 1473-1479.
4. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18: 636-645.
5. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31: 344-350.
6. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013; 31: 337-343.
7. Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008;116: 597-602.
8. Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009;174: 1149-1153.
9. van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010;16: 1597-1604.
10. Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006;65: 988-994.
11. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19) (q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66: 9852-9861.
12. Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011;333: 1453-1455.
13. Yip S, Butterfield YS, Morozova O, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 2012;226: 7-16.
14. Sahm F, Koelsche C, Meyer J, et al. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol 2012;123: 853-860.
15. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas. Oncotarget 2012;3: 709-722.
16. Reifenberger G, Kros JM, Louis DN, et al. Oligodendroglioma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). WHO Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer: Lyon, France, 2007, pp 54-67.
17. Dong Z, Pang JS, Ng MH, et al. Identification of two contiguous minimally deleted regions on chromosome 1p36.31-p36.32 in oligodendroglial tumours. Br J Cancer 2004;91: 1105-1111.
18. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7: 248-249.
19. Tseng AS, Tapon N, Kanda H, et al. Capicua regulates cell proliferation downstream of the receptor tyrosine kinase/ras signaling pathway. Curr Biol 2007;17: 728-733.
20. Jiménez G, Guichet A, Ephrussi A, Casanova J. Relief of gene repression by torso RTK signaling: role of capicua in Drosophila terminal and dorsoventral patterning. Genes Dev 2000;14: 224-231.
21. Astigarraga S, Grossman R, Díaz-Delfín J, et al. A MAPK docking site is critical for downregulation of Capicua by Torso and EGFR RTK signaling. EMBO J 2007;26: 668-677.
22. Lee CJ, Chan WI, Cheung M, et al. CIC, a member of a novel subfamily of the HMG-box superfamily, is transiently expressed in developing granule neurons. Brain Res Mol Brain Res 2002;106: 151-156.
23. He L, Liu J, Collins I, et al. Loss of FBP function arrests cellular proliferation and extinguishes c-myc expression. EMBO J 2000;19: 1034-1044.
24. Wang X, Avigan M, Norgren RB Jr. FUSE-binding protein is developmentally regulated and is highly expressed in mouse and chicken embryonic brain. Neurosci Lett 1998;252: 191-194.
25. Duncan R, Bazar L, Michelotti G, et al. A sequencespecific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNAbinding motif. Genes Dev 1994;8: 465-480.
26. Hsiao HH, Nath A, Lin CY, et al. Quantitative characterization of the interactions among c-myc transcriptional regulators FUSE, FBP, and FIR Biochemistry 2010;49: 4620-4634.
27. Trost D, Ehrler M, Fimmers R, et al. Identification of genomic aberrations associated with shorter overall survival in patients with oligodendroglial tumors. Int J Cancer 2007;120: 2368-2376.
28. Idbaih A, Dalmasso C, Kouwenhoven M, et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. J Neurooncol 2011;103: 221-230.
29. Ducray F, Idbaih A, de Reyniès A, et al. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 2008; 7:41.
30. Cooper LA, Gutman DA, Long Q, et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One 2010;5:e12548.
31. van den Bent MJ, Gravendeel LA, Gorlia T, et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res 2011;17: 7148-7155.
32. Alentorn A, Sanson M, Idbaih A. Oligodendrogliomas: new insights from the genetics and perspectives. Curr Opin Oncol 2012;24: 687-693.
33. Snuderl M, Eichler AF, Ligon KL, et al. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res 2009;15: 6430-6437.